Механизмы устойчивости опухолей к цисплатину
цисплатина. Результати цієї роботи вказують на можливість участі
продукту гена v-src в індукції резитентності до цисплатина шляхом
модуляції деяких шляхів репарації ДНК [111].
Ампліфікація гена сорцина (кальцій-звязуючого білка з
молекулярною масою 19-22кД) в деяких модельних системах асоціювалася
з резистентним фенотипом [112]. Важко зараз сказати, чи є
резистентність пов`язаною саме з сорцином чи разом з геном сорцина у
клітинах ампліфіковані і інші, більш важливі для розвитку
резистентності гени.
Таким чином резистентність до цисплатина має комплексний
характер і пов`язана з рядом особливостей клітин на рівні
цитоплазматичної мемрани, внутрішньоклітинних систем детоксикації,
систем репарації та порушення функціональної активності генів p 53,
bcl-2, fos, mdm 2, nm23та інших.
Список літератури
1. Чехун ВФ. Роль плазматичних мембран нормальних і пухлинних клітин в
механізмі реалізації цитотоксичних ефектів координаційних сполук
платини [Автореф дис ... докт мед наук]. Киев: ИЭПОР, 1994. 40 сс.
2. Scanlon KJ, Kashani-Sabet M, Tone T, Funato T. Cisplatin
resistance in human cancers. Pharmacol Ther 1991; 52:385-406.
3. Gately DP, S.B.Howell SB. Cellular accumulation of the anticancer
agent cisplatin. Br J Cancer 1993; 67:1171-6.
4. Ohmori T, Morikage T. The mechanism of the difference in cellular
uptake of platinum derivatives in non-small cell lung cancer cell
line (PC-14) and its cisplatin-resistant subline (PC-14/CDDP). Jpn J
Cancer Res 1993; 84: 83-92.
5. Scanlon KJ, Safistein RL, Thies H, Gross RB, Waxman S, Guttenplan
JB. Inhibition of amino acid transport by cis-
diamminedichloroplatinum (II) derivatives in L1210 murine leukemia
cells. Cancer Res 1983; 43: 4211-5.
6. Andrews PA, Velury S, Mann SC, Howell SB. Cis-
diamminedichloroplatinum II accumulation in sensitive and resistant
human ovarian carcinoma cells. Cancer Res 1988; 48: 68-73.
7. Richon VM, Schulte N, Eastman A. Multiple mechanisms of
resistance to cis-diamminedichloroplatinum (II) in murine leukemia
L1210 cells. Cancer Res 1987 47: 2056-61.
8. Zaman GJR, Lakelma J, Tellingen O, Beijnen J, Dekker H,
Paulusma C, Oude Elferink RPJ, Baas F, Borst P. Role of glutathione
in the export of compaunds from cells by the multidrug-resistance-
associated protein. Proc Natl Acad Sci USA 1995; 92:7690-4.
9. Muller V, Meijer C, Zaman GJR. Overexpression of the gene encoding
the multidrug resistance-assiciated protein results in increased ATP-
dependent glutathione S-conjugate transport. Proc Natl Acad Sci USA
1994; 91: 13033-7.
10. Ishikawa T, Ali-Osman F. Glutathione-associated cis-
diamminedichloroplatinum (II) metabolism and ATP-dependent efflux
from leukemia cells. J Biol Chem 1993; 268: 20116-25.
11. Laurent G, Erickson LC, Sharkey NA, Kohn KW. DNA cross-linking
and cytotoxicity induced by cis-diamminedichloroplatinum (II) in
human normal and tumor cell lines. Cancer Res 1981; 41: 3347-51.
12. Sorenson CM, Barry MA, Eastman A. Analysis of events associated
with cell cycle arrest at G2 phase and cell death induced by
cisplatin. J Natl Cancer Inst 1990; 82: 749-55.
13. Olivero OA, Chang PK, Lopez-larraza DM, Semino-Mora MC, Poirier
MC. Preferential formation and decreased removal of cisplatin-DNA
adducts in chinese hamster ovary cell mitochondrial DNA as compared
to nuclear DNA. Mutat Res 1997, 391(1-2): 79-86.
14. Giurgiovich AJ, Diwan BA, Olivero OA, Anderson LM, Rice JM,
Poirier MC. Elevated mitochondrial cisplatin-DNA adduct levels in rat
tissues after transplacental cisplatin exposure. Carcinogenesis 1997,
18(1): 93-6.
15. Gorczyca W, Gong I, Ardelt B, Traganos F, Darzynkiewicz Z. The
cell cycle related differences in susceptibility of HL-60 cells to
apoptosis induced by various antitumor agents. Cancer Res 1993,
53(13): 3186-92.
16. el Alaoui S, Lawry J, Griffin M. The cell cycle and induction of
apoptosis in a hamster fibrosarcoma cell line treated with anticancer
drugs: its importance to solid tumor chemotherapy. J Neurooncol 1997,
31(1-2): 195-207.
17. Vaisman A, Varchenko M, Said I, Chaney SG. Cell cycle changes
associated with formation of Pt-DNA adducts in human ovarian
carcinoma cells with different cisplatin sensitivity. Cytometry 1997,
27(1): 54-64.
18. Nishio K, Saigo N. Effect of cisplatin on cell cycle regulators.
Gan To Kagaku Ryoho 1994, 21(3): 289-94.
19. Dimanche-Boitrel MT, Micheau O, Hamman A, Haugg M, Eymin B,
Chauffert B, Solary E. Contribution of the cyclin-dependent kinase
inhibitor p27KIP1 to the confluence-dependent resistance of HT 29
human colon carcinoma cells. Int J Cancer 1998, 77(5): 796-802.
20. Gill JS, Mindebank AJ. Cisplatin-induced apoptosis in rat dorsal
root ganglion neurons is associated with attempted entry into the
cell cycle. J Clin Invest 1998, 101(12): 2842-50.
21. Megyesi J, Safirstein RL, Price PM. Induction of p 21
WAF1?CIP1/SDI1 in kidney tubule cells affects the course of cisplatin-
induced acute renal failure. J Clin Invest 1998, 101(4): 777-82.
22. Otto AM, Paddenberg R, Schubert S, Mannherz HG. Cell cycle
arrest, micronucleus formation, and cell death in growth inhibition
of MCF-7 breast cancer cells by tamoxifen and cisplatin. J Cancer Res
Clin Oncol 1996, 122(10): 603-612.
23. Boersma AW, Nooter K, Oostrum RG, Stoter G. Quantification of
apoptotic cells with fluorescein isothiocyanate-labeled annexin V in
chinese hamster ovary cells cultures treated with cisplatin.
Cytometry 1996, 24(2): 123-130.
24. Ormerod MG, O`Neill C, Robertson D, Helland LR, Harrap KR. Cis-
diamminedichloroplatinum (II)-induced cell death through apoptosis in
sensitive and resistant human ovarian carcinoma cell lines. Cancer
Chemother Pharmacol 1996, 37(5): 463-471.
25. Uslu R, Jewett A, Bonavida B. Sensitization of human ovarian
tumor cells by subtoxic CDDP to anti-fas antibody mediated
cytotoxicity and apoptosis. Gynecol Oncol 1996, 62(2): 282-91.
26. Fulda S, Sieverts H, Friesen C, Herr I, Debatin KM. The CD95(APO-
1/Fas) system mediates drug-induced apoptosis in neuroblastoma cells.
Cancer Res 1997, 57(17): 3823-9.
27. McGahon AJ, Costa Pereira AP, Daly L, Cotter TG. Chemotherapeutic
drug-induced apoptosis in human leukaemic cells is independent of the
Fas(APO-1/CD95) receptor/ligand system. Br J Haematol 1998, 101(3):
539-47.
28. Antoku K, Liu Z, Johnson DE. Inhibition of caspase proteases by
CrmA enhances the resistance of human leukemia cells to multiple
chemotherapeutic agents. Leukemia 1997, 11(10): 1665-72.
29. Chen Z, Naito M, Mashima T, Tsuruo T. Activation of actin-
cleavable interleukin 1 beta-converting enzyme (ICE) family protease
CPP-32 during chemotherapeutic agent-induced apoptosis in ovarian
carcinoma cells. Cancer Res 1996, 56(22): 5224-9.
30. Marissen WE, Lloyd RE. Eukariotic translation initiation factor
4G is targeted for proteolytic cleavage by caspase 3 during
inhibition of translation in apoptotic cells. Mol Cell Biol 1998,
18(12): 7565-74.
31. Kraker AJ, Moore CW. Accumulation of cis-diamminedichloroplatinum
(II) and platinum analogues by platinum-resistant murine leukemia
cells in vitro. Cancer Res 1988; 48: 9-13.
32. Eichholtz-Wirth H, Hietel B. The relationship between cisplatin
sensitivity and drug uptake into mammalian cells in vitro. Br J
Cancer 1986; 54: 239-43.
33. Kawai K, Kamatani N, Georges E, Ling V. Identification of a
membrane glycoprotein overexpression in murine lymphoma sublines
resistant to cis- diamminedichloroplatinum (II). J Biol Chem 1990;
265: 13137-42.
34. Ishikawa T, Wright CD, Ishizuka H. GS-X pump Is functionally
overexpressed in cis-diamminedichloroplatinum (II)-resistant human
leukemia HL-60 Cells and downregulated by cell differentiation. J
Biol Chem 1994; 269: 29085-93.
35. Goto S, Yoshido K, MoriKawa T, Urata Y, Suzuki K,. Kondo T.
Augmentation of transport for cisplatin-glutathione adduct in
cisplatin-resistant cancer cells. Cancer Res 1995; 55: 4297-301.
36. Veneroni S, Zaffaroni N, Daidone MG, Benini E, Villa R,
Silvestrini R. Expression of P-glycoprotein and in vitro or in vivo
resistance to doxorubicin and cisplatin in breast and ovarian
cancers. Eur J Cancer 1994; 30A: 1002-7.
37. Jedlitschky G, Leier J, Buchholz U, Barnouin K, Kurz G, Keppler
D. Transport of glutathione, glucuronate, and sulfate conjugates by
the MRP gene-encoded conjugate export pump. Cancer Res 1996; 56: 988-
94.
38. Okuyama T, Maehara Y, Endo K, Baba H, Adachi Y, Kuwano M,
Sugimachi K. Expression of glutathione S-transferase-pi and
sensitivity of human gastric cancer cells to cisplatin. Cancer 1994;
74: 1230-6.
39. Awasthi S, Sharma R, Singhal SS, Herzog NK, Chaubey M, Awasthi
YC. Modulation of cisplatin cytotoxicity by sulphasalazine. Br J
Cancer 1994; 70: 190-4.
40. Bongers V, Snow GB, Braakhuis BJM. The role of glutathione S-
transferases in head and neck squamous cell carcinogenesis. Eur J
Cancer 1995; 31B: 349-54.
41 Minagawa Y, Kigawa J, Ishihara H, Itamochi H, Terakawa N.
Synergistic enhancement of cisplatin cytotoxicity by SN-38, an active
metabolite of CPT-11, for cisplatin-resistant HeLa cells. Jpn J
Cancer Res 1994; 85: 966-71.
42. Boscia RE, Korbut T, Holden SA, Ara G, Teicher BA. Interaction of
topoisomerase I inhibitors with radiation in cis-
Diamminedichloroplatinum (II)-sensitive and -resistant cells in vitro
and in the FSAIIC fibrosarcoma in vivo. Int J Cancer 1993; 53: 118-
23.
43. Kikuchi Y, Hirata J, Yamamoto K, Ishi K, Kita T, Kudoh K, Tode
T, Nagata I, Taniguchi K, Kuwano M. Altered expression of ?-
glutamylcysteine synthetase, metallothionein and topoisomerase I or
II during acquisition of drug resistance to cisplatin in human
ovarian cancer cells. Jpn J Cancer Res 1997; 88: 213-7.
44. Hirata J, Kikuchi Y, Kita T, Imaizumi EE, Tode T, Ishii K, Kudoh
K, Nagata I. Modulation of sensitivity of human ovarian cancer cells
to cis-diamminedichloroplatinum (II) by 12-O-tetradecanoylphorbol-13-
acetate and D,L-Buthionine-S,R-Sulphoximine. Int J Cancer 1993; 55:
521-7.
45.Sugimoto C, Matsukawa S, Fujieda S, Noda I, Tanaka N, Tsuzuki H,
Saito H. Involvement of intracellular glutathione in induction of
apoptosis by cisplatin in a human pharyngeal carcinoma cell line.
Anticancer Res 1996; 16: 675-80.
46. Pendyala L, Perez R, Weinstein A, Zdanowicz J, Creaven PJ. Effect
of glutathione depletion on the cytotoxicity of cisplatin and
iproplatin in a human melanoma cell line. Cancer Chemother Pharmacol
1997, 40 (1): 38-44.
47. Kurokawa H, Nishio K, Ishida T, Arioka H, Fukuoka K, Nomoto T,
Fukumoto H, Yokote H, Saijo N. Effect of glutathione depletion on
cisplatin resistance in cancer cells transfected with the ?
-glutamylcysteine synthetase gene. Jpn J Cancer Res 1997; 88: 108-
10.
48. Campling BG, Baer K, Baker HM, Lam YM. Cole SPC. Do glutathione
and related enzymes play a role in drug resistance in small cell lung
cancer ctll lines? Br J Cancer 1993; 68: 327-35.
49. Kodera Y, Akiyama S, Isobe K, Kondo K, Ito K, Yamauchi M, Takagi
H. Expression of ?-glutathione S-transferase gene (GSTP1) in gastric
cancer: lack of correlation with resistance against cis-
diamminedichloroplatinum (II). Eur J Cancer 1994; 30A: 2158-62.
50. Mellish KJ, Kelland LR, Harrap KR. In vitro platinum drug
chemosensitivity of human cervical squamous cell carcinoma cell lines
with intrinsic and acquired resistance to cisplatin. Br J Cancer
1993; 68: 240-50.
51. Eichholtz-Wirth H, Reidel G, Hietel B. Radiation-induced
transient cisplatin resistance in murine fibrosarcoma cells
associated with elevated metallothionein content. Br J Cancer 1993;
67: 1001-6.
52. Lazo JS, Basu A. Metallothionein expression and transient
resistance to electrophilic antineoplastic drugs. Semin Cancer Biol
1991; 2: 267-71.
53. Hishikawa Y, Abe SI, Kinugasa S, Yoshimura H, Monden N.
Overexpression of metallothionein correlates with chemoresistance to
cisplatin and prognosis in esophageal cancer. Oncology 1997; 54: 342-
7.
54. Vaisman A, Vachenko M, Said I, Chaney SG. Cell cycle changes
associated with formation of Pt-DNA adducts in human ovarian
carcinoma cells with different cisplatin sensitivity. Cytometry 1997;
27: 54-64.
55. Hill BT, Scanlon KJ, Hansson J, Harstrick A, Pera M,
Fichtinger-Schepman AMJ, Shellard SA. Deficient repair of cisplatin-
DNA adducts identified in human testicular teratoma cell lines
established from tumours from untreated patients. Eur J Cancer 1994;
30A: 832-7.
56. Johnson SW, Swiggard PA, Handel LM, Godwin AK, Ozols RF, Hamilton
TC. Relationship between platinum-DNA adduct formation and removal
and cisplatin cytotoxicity in cisplatin-sensitive and resistant human
ovarian cancer cells. Cancer Res 1994, 54: 5911-6.
57. Turchi JJ, Li M, Henkels KM. Cisplatin-DNA binding specificity
of calf high mobility group I protein. Biochem 1996; 35: 2992-3000.
58.Ikeda S, Ozaki K. Action of mitochondrial endonuclease G on DNA
damaged by L-ascorbic acid, peplomycin, and cis-
diamminedichloroplatinum (II). Biochem Biophys Res Commun 1997,
235(2): 291-4.
59. Bissett D, McLaughlin K, Kelland LR, Brown R. Cisplatin-DNA
damage recognition proteins in human tumor extracts. Br J Cancer
1993; 67:742-8.
60. McLaughlin K, Coren G, Masters J, Brown R. Binding activities of
cis-platin-damage-recognition proteins in human tumor cell lines. Int
J Cancer 1993; 53: 662-6.
61. Brown R, Hirst GL, Gallagher WM, McIlwrath AJ, Margison GP, Zee
AG, Anthoney DA. HMLN1 expression and cellular responses of ovarian
tumor cells to treatment with cytotoxic anticancer agents. Oncogene
1997, 15(1): 45-52.
62. Lanzi C, Perego P, Supino R, Romanelli S, Pensa T, Carenini N,
Viano I, Colangelo D, Leone R, Apostoli P, Cassinelli G, Gambetta RA,
Zunino F. Decreased drug accumulation and increased tolerance to DNA
damage in tumor cells with a low level of cisplatin resistance.
Biochem Pharmacol 1998, 55(8): 1247-54.
63. Fishel R, Ewel A, Lescoe MC. Purified human MSH2 protein binds to
DNA containing mismatched nucleotides. Cancer Res 1994; 54: 5539-42.
64. Loeb LA. Microsatellite instability: marker of a mutator
phenotype in cancer. Cancer Res 1994; 54: 5059-63.
65. Chu G. Cellular responces to Cisplatin. J Biol Chem 1994; 269:
787-90.
66. Sorenson CM, Eastman A. Influence of cis-Diamminedichloroplatinum
(II) on DNA synthesis and cell cycle progression in excision repair
proficient and deficient hamster ovary cells. Cancer Res 1988; 48:
6703-7.
67. Li Q, Gardner K, Zhang L, Tsang B, Bostick-Bruton F, Reed E.
Cisplatin induction of ERCC-1 mRNA expression in A2780/CP70 human
ovarian cancer cells. J Biol Chem 1998, 273 (36): 23419-25.
68. Husain A, He G, Venkatraman ES, Spriggs DR. BRCA1 up-regulation
is associated with repair-mediated resistance to cis-
diamminedichloroplatinum (II). Cancer Res 1998, 58 (6): 1120-3.
69. Mestdach N, Pommery N, Saucier JM, Hecquet B, Founier C,
Slomianny C, Teissier E, Henichart JP. Chemoresistance to doxorubicin
and cisplatin in a murine cell line. Analysis of P-Glycoprotein,
topoisomerase II activity, glutathione and related enzymes.
Anticancer Res 1994; 14: 869-74.
70. Kondo H, Kanzawa F, Nishio K, Saito S, Saijo N. In vitro and
in vivo effects of cisplatin and etoposide in combination on small
cell lung cancer cell lines. Jpn J Cancer Res 1994; 85: 1050-6.
71. Jong S, Timmer-Bosscha H, Vries EGE, Mulder NH. Effect of
novobiocin on cisplatin cytotoxicity and DNA interstrand cross-link
formation in a cisplatin-resistant, small-cell lung carcinoma cell
line. Int J Cancer 1993; 53: 110-7.
72. Guchelaar H-J, Timmer-Bosscha H, Dam-Meiring A, Uges DRA,
Oosterhuis JW, Vries EGE Mulder NH. Enhancement of cisplatin and
etoposide cytotoxicity after all-trans retinoic-acid-induced cellular
differentiation of a murine embryonal carcinoma cell line. Int J
Cancer 1993; 55: 442-7.
73. Seki S, Hongo A, Zhang B, Akiyama K, Sarker AH, Kudo T.
Inhibition of cisplatin-mediated DNA damage in vitro by
ribonucleotides. Jpn J Cancer Res 1993; 84: 462-7.
74. Parekh HK, Simpkins H. The differential expression of
citokeratin 18 in cisplatin-sensitive and -resistant human ovarian
adenocarcinoma cells and its association with drug sensitivity.
Cancer Res 1995; 55: 5203-6.
75. Mirakhur B, Parekh HK, Simpkins H. Expression of the cisplatin
resistance phenotype in a human ovarian carcinoma cell line
segregates with chromosomes 11 and 16. Cancer Res 1996; 56: 2256-
62.
76. Mueller H, Eppeberger U. The dual role of mutant p 53 protein in
chemosensitivity of human cancers. Anticancer Res 1996, 16 (6B): 3845-
8.
77. Kawasaki t, Tomita Y, Bilim V, Takeda M, Takahashi K, Kumanishi
T. Abrogation of apoptosis induced by DNA-damaging agents in human
bladder-cancer cell lines with p 21/WAF1/CIP1 and/or p 53 gene
alterations. Int J Cancer 1996, 68 (4): 501-5.
78. Kondo S, Barna BP, Kondo Y, Tanaka Y, Casey G, Liu J, Morimura T,
Kaakaji R, Peterson JW, Werbel B, Barnett GH. WAF1/CIP1 increases the
susceptibility of p 53 non-functional malignant glioma cells to
cisplatin-induced apoptosis. Oncogene 1996, 13 (6): 1279-85.
79. Li G, Tang L, Zhou X, Tron V, Ho V. Chemotherapy-induced
apoptosis in melanoma cells is p 53 dependent. Melanoma Res 1998, 8
(1): 17-23.
80. Biagosklonny MV, El-Deiry WS. Acute overexpression of wt p 53
facilitates anticancer drug-induced death of cancer and normal cells.
Int J Cancer 1998, 75 (6): 933-940.
81. Li R, Sutphin PD, Schwartz D, Matas D, Almog N, Wolkowicz R,
Goldginger N, Pei H, Prokocimer M, Rotter V. Mutant p 53 protein
interferes with p 53-independent apoptotic pathways. Oncogene 1998,
16 (25): 3269-77.
82. Vasey PA, Jones NA, Jenkins S, Dive C, Broun R. Cisplatin,
camptothecin, and taxol sensitivities of cells with p 53-associated
multidrug resistance. Mol Pharmacol 1996, 50 (6): 1536-40.
83. Vikhanskaya F, Clerico L, Valenti M, Stazione NS, Broggini M,
Parodi S, Russo P. Mechanism of resistance to cisplatin in a human
ovarian-carcinoma cell line selected for resistance to doxorubicin:
possible role of p 53. Int J Cancer 1997, 72 (1): 155-9.
84. Vaisman A, Varchenko M, Said I, Chaney SG. Cell cycle changes
associated with formation of Pt-DNA adducts in human ovarian
carcinoma cells with different cisplatin sensitivity. Cytometry 1997,
27 (1): 54-64.
85. Siddik ZH, Mims B, Lozano G, Thai G. Independent pathways of p 53
induction by cisplatin and X-rays in a cisplatin-resistant ovarian
tumor cell line. Cancer Res 1998, 58 (4): 698-703.
86. Ju JF, Banerjee D, Lenz HJ, Danenberg KD, Schmittgen TC, Spreas
CP, Schonthal AH, Manno DJ, Hochhauser D, Bertino JR, Danenberg PV.
Restoration of wild-type p 53 activity in p 53-null HL-60 cells
confers multidrug sensitivity. Clin Cancer Res 1998, 4 (5): 1315-22.
87. Fajac A, Da Silva J, Ahomadegbe JC, Rateau JG, Bernaudin JF, Riou
G, Benard J. Cisplatin-induced apoptosis and p 53 gene status in a
cisplatin-resistant human ovarian carcinoma cell line. Int J Cancer
1996, 86 (1): 67-74.
88. Kondo S, Barna BP, Morimura T, Takeuchi J, Yuan J, Akbasak A,
Barnett GH. Interleukin-1-beta-converting enzyme mediates cisplatin-
induced apoptosis in malignant glioma cells. Cancer Res 1995, 55
(24): 6166-71.
89. De Feudis P, Debernardis D, Beccaglia P, Valenti M, Sire GE,
Arzani D, Stanzione S, Parodi S, D`Incalci M, Russo P, Broggini M.
DDP-induced cytotoxicity is not influenced by p 53 in nine human
ovarian cancer cell lines with different p 53 status. Br J Cancer
1997, 76 (4): 474-9.
90. Burger H, Nooter K, Boersma AW, Kortland CJ, Stoter G. Expression
of p 53, Bcl-2 and Bax in cisplatin-induced apoptosis in testicular
germ cell tumor cell lines. Br J Cancer 1998, 77 (10): 1562-7.
91. Ikeguchi M, Tatebe S, Kaibara N, Ito H. Changes in levels of
expression of p 53 and the product of the bcl-2 in lines of gastric
cancer cells during cisplatin-induced apoptosis. Eur Surg Res 1997,
29 (5), 396-402.
92. Pestell KE, Medlow CJ, Titley JC, Kelland LR, Walton MI.
Characterisation of the p 53 status, BCL-2 expression and radiation
and platinum drug sensitivity of a panel of human ovarian cancer cell
lines. Int J Cancer 1998, 77 (6): 913-8.
93. Nakata B, Chung KH, Ogawa M, Yanagawa K, Muguruma K, Inoue T,
Yamashita Y, Onoda N, Maeda K, Sawada T, Sowa. P 53 protein
overexpression as a predictor of the response to themotherapy in
gastric cancer. Surg Today 1998, 28 (6): 595-8.
94. Petty R, Evans A, Duncan I, Kurbacher C, Cree I. Drug resistance
in ovarian cancer – the role of p 53. Payhol Oncol Res 1998, 4 (2):
97-102.
95. Simonian PL, Grillot DA, Andrews DW, Leber B, Nunez G. Bax
homodimerization is not required for Bax to accelarate chemotherapy-
induced cell death. J Biol Chem 1996, 271 (50): 32073-7.
96. Liu JR, Fletcher B, Page C, Hu C, Nunez G Baker V. Bcl-xL is
expressed in ovarian carcinoma and modulates chemotherapy-induced
apoptosis. Gynecol Oncol 1998, 70 (3), 398-403.
97. Miyake H. Hanada N, Nakamura H, Kagawa S, Fujiwara T, Hara I, Eto
H, Gohji K, Arakawa S, Kamidono S, Saya H. Overexpression of Bcl-2 in
bladder cancer inhibits apoptosis induced by cisplatin and adenoviral-
mediated p 53 gebe transfer. Oncogene 1998, 16 (7): 1933-43.
98. Minn AJ, Rudin CM, Boise LH, Thompson CB. Expression of bcl-xl
can confer a multidrug resistance phenotype. Blood 1995, 86 (5): 1903-
10.
99.Simonian PL, Grillot AM, Nunez G. Bcl-2 and Bcl-Xl can
differentially block chemotherapy induced cell death. Blood 1997, 90
(3): 1208-16.
100. Jones NA, Turner J, McIlwrath AJ, Brown R, Dive C. Cisplatin-
and paclitaxel-induced apoptosis of ovarian carcinoma cells and the
relationship between bax and bak up-regulation and the functional
status of p 53. Mol Pharmacol 1998, 53 (3): 819-26.
101. Boersma AW, Nooter K, Burger h, Kortland CJ, Stoter G. Bax
upregulation is an early event in cisplatin-induced apoptosis in
human testicular germ-cell tumor cell line NT2, as quantitated by
flow cytometry. Cytometry 1997, 27 (3): 275-82.
102. Lee JU, Hosotani R, Wada H, Doi R, Kosiba T, Fujimoto K,
Miyamoto Y, Mori C, Nakamura N, Shiota K, Imamura M. Mechanism of
apoptosis induced by cisplatin and VP-16 in PANC-1 cells. Anticancer
Res 1997, 17 (5A): 3445-50.
103. Houldsworth J, Xiao H, Murty VV, Chen W, Ray B, Reuter VE, Bosl
GJ, Chaganti RS. Human male germ cell tumor resistance to cisplatin
is linked to TP53 gene mutation. Oncogene 1998, 16 (18): 2345-9.
104. Sakahura C, Sweeney EA, Shirahama T, Igarashi Y, Hakomori S,
Tsujimoto H, Imanishi T, Ogaki M, Yamazaki J, Hagiwara A, Yamaguchi
T, Sawai K, Takahashi T. Overexpression of bax sensitizes breast
cancer MCF-7 cells to cisplatin and etoposide. Surg Today 1997, 27
(7): 676-9.
105. Kondo S, Shinomura Y, Kanayama S, Higashimoto Y, Kiyohara T,
Zushi S, Kitamura S, Ueyama H, Matsuzawa Y. Modulation of apoptosis
by endogenous Bcl-Xl expression in MKN-45 human gastric cancer cells.
Oncogene 1998, 17(20): 2585-91.
106. Nakata B, Muguruma K, Hirakawa K, Chung YS, Yamashita Y, Inoue
T, Matsuoka T, Onoda N, Kato Y, SowaM. Predictive value of Bcl-2 and
Bax protein expression for chemotherapeutic effect in gastric cancer.
Apilot study. Oncol 1998, 55(6): 543-7.
107. Boku N, Chin K, Hosokawa K, Ohtsu A, Tajiri H, Yoshida S, Yamao
T, Kondo H, Shirao K, Shimada Y, Saito D, Hasebe T, Mukai K, Seki S,
Saito H, Johnston PG. Biological markers as a predictor for response
and prognosis of unresectable gastric cancer patients treated with 5-
fluorouracil and cis-platinum. Clin Cancer Res 1998, 4 (6): 1469-74.
108. Herod JJ, Eliopoulos AG, Warwick J, Niedobitek G, Young LS, Kerr
DJ. The prognostic significance of bcl-2 and p 53 expression in
ovarian carcinoma. Cancer Res 1996, 56 (9): 2178-84.
109. Muguruma K, Nakata B, Hirakawa K, Yamashita Y, Onoda N, Inoue T,
Matsuoka T, Kato Y, Sowa. P 53 and Bax protein expression as
predictor of chemotherapeutic effect in gastric carcinoma. Gan To
Kagaku Ryoho 1998, 3: 400-3.
110. Ferguson AW, Flatow U, MacDonald NJ, Larminat F, Bohr VA,
Steeg PS. Increased sensitivity to cisplatin by nm23-transfected
tumor cell lines. Cancer Res 1996; 56: 2931-5.
111.Masumoto N, Nakaano S. Cell signalling and CDDP resistance. Gan
To Kagaku Ryoho 1997, 24(4): 424-30.
112. Demidova NS, Ilynskaya GV, Shiryaeva OA, Chernova OB, Goncharova
SA, Kopnin BP. Decreased sensitivity of multidrug-resistant tumor
cells to cisplatin is correlated with sorcin gene co-amplification.
Neoplasma 1995; 42: 195-201.
Страницы: 1, 2, 3
|